Literature DB >> 9951268

[Premedication with intranasal midazolam in children of various ages].

R Vivarelli1, F Zanotti, D Battaglia, G Caggese, G Stella, G Gilli, A Guberti.   

Abstract

BACKGROUND AND AIM: To evaluate the efficacy of premedication with midazolam (mdz) administered using a nasal route compared to diazepam (dz) administered by mouth in children of different ages. EXPERIMENTAL
DESIGN: A comparative type study was performed in randomly selected pediatric patients undergoing surgery. The study lasted 3 months.
SETTING: Recovery room and operating theatre for Pediatric Surgery and ENT. PATIENTS: A total of 248 patients were studied, divided into 3 age groups: group A were aged under 2 years; group B were pre-school age and group C were school-age. OPERATIONS: Two subgroups were formed based on the premedication used: group M = 0.2 mg/kg of mdz using a nasal route on arrival in the operating unit; group D = 0.2 mg/kg of dz per os 45' before induction. PARAMETERS STUDIED: In addition to acceptance of treatment, which was deemed to be good, poor or refused, the authors evaluated the level of sedation (score from 5 to 1: awake-asleep), anxiety on entering SO (score from 1 to 4: none-excessive) and the level of collaboration during the induction of general anesthesia (score 1-4: excellent-nil).
RESULTS: The nasal route was well accepted by 59% of patients in group A, 62% of group B and 97% of group C. Statistical analysis using Kruskall Wallis test showed significant differences in groups A and B between the two subgroups M and D for all the parameters studied, whereas there were no significant differences in group C.
CONCLUSIONS: Premedication with mdz using a nasal route was safe and efficacious, above all in early and later infancy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9951268

Source DB:  PubMed          Journal:  Minerva Anestesiol        ISSN: 0375-9393            Impact factor:   3.051


  1 in total

1.  Atomised intranasal midazolam spray as premedication in pediatric patients: comparison between two doses of 0.2 and 0.3 mg/kg.

Authors:  Namita M Baldwa; Amit V Padvi; Nandini M Dave; Madhu B Garasia
Journal:  J Anesth       Date:  2012-03-01       Impact factor: 2.078

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.